Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03963414
Title A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Vinicius Ernani

lung small cell carcinoma


Carboplatin + Durvalumab + Etoposide + Tremelimumab

Carboplatin + Durvalumab + Etoposide

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.